

Cardiovascular and Renal Drugs Advisory Committee

December 11, 2007

Sheraton College Park Hotel

Beltsville, Maryland

Draft Meeting Roster

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBERS

(Voting)

Steven D. Findlay, M.P.H.

Consumer Representative
Health Policy Analyst
Consumers Union
Washington, DC

Frederick J. Kaskel, M.D., Ph.D.

Professor, Department of Pediatrics
Children's Hospital at Montefiore
Albert Einstein College of Medicine of
Yeshiva University
Bronx, NY

Robert A. Harrington, M.D., F.A.C.C.

Professor of Medicine, Division of Cardiology
Department of Medicine
Duke University Medical School
Duke Clinical Research Institute
Durham, NC

Abraham Michael Lincoff, M.D., F.A.C.C.

Professor of Medicine
Department of Cardiovascular Medicine
The Cleveland Clinic Foundation
Cleveland, OH

William R. Hiatt, M.D. (Chair)

Professor of Medicine
University of Colorado
Colorado Prevention Center
Denver, CO

TEMPORARY MEMBERS (Voting)

Barry M. Massie, M.D.

Professor of Medicine
University of California, San Francisco
Chief, Cardiology Section
San Francisco VA Hospital
San Francisco CA

Cardiovascular and Renal Drugs Advisory Committee

December 11, 2007

Sheraton College Park Hotel

Beltsville, Maryland

Draft Meeting Roster

Page 2

INDUSTRY REPRESENTATIVE (Non-Voting)

Jonathan C. Fox, M.D., Ph.D., F.A.C.C.

(Acting) Industry Representative
VP Clinical Therapeutic Area, CVGI
AstraZeneca LP, PO Box 15437
Wilmington, DE

GUEST SPEAKER (Non-Voting)

Christopher B. Granger, M.D.

Cardiologist
Department of Medicine
Division of Cardiovascular Medicine
Duke University School of Medicine

FDA PARTICIPANTS (Non-Voting)

Norman Stockbridge, M.D.

Director, Division of Cardiovascular and Renal Drug Products
FDA/CDER

Robert Temple, M.D.

Director, Office of Drug Evaluation I (ODEI)
FDA/CDER

Ellis Unger, M.D.

Deputy Director, Division of Cardiovascular and Renal Drug Products
FDA/CDER